Your browser doesn't support javascript.
loading
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma.
Schmidts, Andrea; Srivastava, Ambike A; Ramapriyan, Rishab; Bailey, Stefanie R; Bouffard, Amanda A; Cahill, Daniel P; Carter, Bob S; Curry, William T; Dunn, Gavin P; Frigault, Matthew J; Gerstner, Elizabeth R; Ghannam, Jack Y; Kann, Michael C; Larson, Rebecca C; Leick, Mark B; Nahed, Brian V; Richardson, Leland G; Scarfò, Irene; Sun, Jing; Wakimoto, Hiroaki; Maus, Marcela V; Choi, Bryan D.
Affiliation
  • Schmidts A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Srivastava AA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Ramapriyan R; Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Bailey SR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Bouffard AA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Cahill DP; Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Carter BS; Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Curry WT; Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Dunn GP; Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Frigault MJ; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Gerstner ER; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA (E.R.G.).
  • Ghannam JY; Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Kann MC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Larson RC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Leick MB; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Nahed BV; Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Richardson LG; Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Scarfò I; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Sun J; Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Wakimoto H; Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Maus MV; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Choi BD; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Neurooncol Adv ; 5(1): vdac185, 2023.
Article in En | MEDLINE | ID: mdl-36751672
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Neurooncol Adv Year: 2023 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Neurooncol Adv Year: 2023 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido